MediWound (NASDAQ:MDWD) completed enrollment in a Phase 3 study evaluating NexoBrid for the treatment of burns in patients 18 years of age and younger.
NexoBrid is a topically administered biological product that enzymatically removes burn tissue without harming viable tissue.
The trial enrolled 145 hospitalized children with severe thermal burns covering one-to-30% of total body surface area. Patients will receive either NexoBrid or the standard-of-care treatment, with follow-up periods at 12 months and at 24 months.
“The current mode of pediatric burn management requires intensive medical therapy, which poses challenges due to the surgical complexities in treating young patients with severe burns,” Sharon Malka, MediWound’s CEO, said in a statement.
“Having NexoBrid as a non-surgical option provides a minimally-invasive alternative to the current surgical standard-of-care for treating severe burns in pediatric patients,” she added.
MediWound expects to report topline results from the 12-month follow up during the second half of 2021.
